Drug intelligence / Profile preview

BP-C2

Development stage: Phase 1
Lead developer: Meabco
Modality: Small Molecules
Administration: Oral

Overview

BP-C2 is a novel lignin-derived polyphenolic composition complexed with ammonium molybdate, currently under development by Meabco Inc. It is being investigated as a radioprotective and radiomitigative agent for the treatment and prevention of radiation-induced injuries, including gastrointestinal acute radiation syndrome (GI-ARS) and cutaneous radiation injury (CRI). The drug is intended for use both as a medical countermeasure for nuclear or radiological emergencies and as a supportive therapy for cancer patients receiving radiotherapy. BP-C2 is being advanced through IND-enabling studies under the FDA's Animal Rule pathway, with significant funding and support from the National Institute of Allergy and Infectious Diseases (NIAID).

Other names: lignin-derived polyphenolic composition with ammonium molybdate

Beyond the preview

Go deeper on BP-C2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BP-C2.

Explore the full profile